Multimodale komplementäre Therapie des fortgeschrittenen Pankreaskarzinoms

Autor:	F. Migeod, I. Krautgartner, G. Schrittwieser, E. D. Hager, R. Koomagi
Rok vydání:	2009
Předmět:	Hyperthermia Cancer Research medicine.medical_specialty business.industry medicine.medical_treatment Mitomycin C Multimodal therapy medicine.disease Gastroenterology Surgery Bacterial vaccine Regimen Mistletoe extract Internal medicine Medicine Hormone therapy business Tumor marker
Zdroj:	Deutsche Zeitschrift für Onkologie. 41:16-26
ISSN:	1439-0930 1617-5891
Popis:	In a prospective study 46 patients with far advanced, surgically not totally resectable pancreatic carcinomas underwent a multimodal, complementary therapy. All patients received: loco-regional radiofrequency deep hyperthermia (13.56 MHz), enzyme-therapy (Kreon®, Wobenzym®), anti-hormonal therapy (tamoxifen, flutamid, LH-RH-Analoga), immunomodulating agents (thymus-peptides, mistletoe extract, cimetidine, prostaglandine-antagonists), differentiating agents (high-dose vitamin A-E-palmitate, alpha-hydroxycalciferol, coumarines), endogenous hyperpyrexia with a mixed bacterial vaccine (Vaccineurin®). Some patients in progress under this regimen were treated with 5-FU, Mitomycin C, α-Interferon, combined with loco-regional deep hyperthermia. Results: Median overall survival was 10.8 months with a 5-year-survival rate of 9 %. Most patients experienced partially excellent improvement in quality of life (gain of appetite and weight, pain relief, improvement in general condition) and clinical criteria (reduction of ascites, jaundice and tumor mass, destruction of metastatic focuses, clinical chemistry and decrease of tumor marker CEA and CA 19-9).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::22af4e20cb8790fce6ffbf95c3c8b2a5 https://doi.org/10.1055/s-0029-1213509 Zobrazit plný text záznamu